CRYZ

Across TCGA pan-cancer cohorts, CRYZ mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRYZ data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRYZ mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRYZ expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where CRYZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.973	0.688	.013	24	view →
PDAC	DFS	Tertile	All	0.406	0.213	.018	6	view →
UCEC	DFS	Tertile	All	0.912	0.747	.043	4	view →
HNSC	DFS	Quartile	II,III,IV	0.888	0.982	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRYZ–CCRCC (DFS)

Open the CCRCC breakdown →